Reversible cardiomyopathy complicating intrathecal baclofen withdrawal: a case report.
This case report is about reversible cardiomyopathy associated with intrathecal baclofen withdrawal. Previous literature has reported that enteral baclofen does not adequately control intrathecal baclofen withdrawal. In our case, coronary atherosclerosis did not play a role in the development of the cardiomyopathy. However, reinstitution of intrathecal baclofen promptly resulted in improvement. One could hypothesize that myocardial stunning from sympathetic hyperactivity led to a similar cardiomyopathy reported with catecholamine excess or acute sympathomimetic poisoning.
Pizon
Anthony F
AF
University of Pittsburgh School of Medicine, Division of Medical Toxicology, Pittsburgh, PA, USA. pizonaf@upmc.edu
Lovecchio
Frank
F
D001418:Baclofen / Q000008:administration & dosage / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D004359:Drug Therapy, Combination; D006801:Humans; D015918:Infusion Pumps, Implantable; D007278:Injections, Spinal; D007441:Intubation, Gastrointestinal; D008140:Lorazepam / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000009:adverse effects*; D015742:Propofol / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000209:etiology*; D016896:Treatment Outcome
D009125:Muscle Relaxants, Central; D001418:Baclofen; D008140:Lorazepam; D015742:Propofol